{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:01:24Z","timestamp":1775232084292,"version":"3.50.1"},"reference-count":16,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health and Care Research (NIHR) Research for Patient Benefit","award":["NIHR203185"],"award-info":[{"award-number":["NIHR203185"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,2,28]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Lung clearance index (LCI\n                      <jats:sub>2.5<\/jats:sub>\n                      ), measured by nitrogen-multiple breath washout (N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW), is a sensitive measure of ventilatory inhomogeneity that can be performed awake\/unsedated from aged 3 years. However, concerns have been raised about the feasibility of LCI\n                      <jats:sub>2.5<\/jats:sub>\n                      measurement by N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW in adults with cystic fibrosis (CF), especially those with advanced lung disease, due to prolonged test durations. We assessed the feasibility, technical acceptability and patient perception of N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW in adults and children\/adolescents with CF within the exercise as an airway clearance technique-CF feasibility trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW (Exhalyzer-D, EcoMedics, Switzerland) was performed on two separate occasions, by multidisciplinary trial staff. Data were centrally over-read (European Cystic Fibrosis Society LCI Core Facility). Outcomes included the proportion of technically acceptable tests, numbers of trials per test, times per trial and total time to perform N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW. Comparisons were made according to age group and forced expiratory volume in 1\u2009s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) category (\n                      <jats:underline>&gt;<\/jats:underline>\n                      70% vs &lt;70% predicted). Participants also completed a questionnaire assessing acceptability and willingness to repeat testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      49 participants (21 female; age: 10\u201355 years, FEV\n                      <jats:sub>1<\/jats:sub>\n                      : 38%\u2013113%\u2009predicted) completed N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW. Median (IQR) test durations were similar for adults (42 (27\u201355) min) and children (37 (26\u201344) min) with CF. Technically acceptable LCI\n                      <jats:sub>2.5<\/jats:sub>\n                      results were obtained for 90\/94 (95.8%) tests. Most participants rated the test easy to perform (87%) and comfortable (93%), with none reporting unwillingness to repeat N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      N\n                      <jats:sub>2<\/jats:sub>\n                      -MBW testing is feasible, technically acceptable and well-tolerated in people with CF across a wide age and disease severity spectrum. With appropriate standardised training and over-reading, LCI\n                      <jats:sub>2.5<\/jats:sub>\n                      represents a robust outcome measure for consideration in CF clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05482048\">NCT05482048<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003905","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:25:21Z","timestamp":1775229921000},"page":"e003905","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Measurement of lung clearance index (LCI\n                    <sub>2.5<\/sub>\n                    ) by nitrogen multiple breath washout (N\n                    <sub>2<\/sub>\n                    -MBW) is feasible and well\u200d-\u200dtolerated by adults and children with cystic fibrosis"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05482048","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-9692","authenticated-orcid":false,"given":"Don S","family":"Urquhart","sequence":"first","affiliation":[{"name":"Department of Child Life and Health, The University of Edinburgh, Edinburgh, UK"},{"name":"Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9541-785X","authenticated-orcid":false,"given":"Emily J","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Child Life and Health, The University of Edinburgh, Edinburgh, UK"},{"name":"Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Miller","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Unit, Western General Hospital, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Bowens","sequence":"additional","affiliation":[{"name":"University Hospitals Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Lacey","sequence":"additional","affiliation":[{"name":"University Hospitals Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Abkir","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"},{"name":"European Cystic Fibrosis Society, Lung Clearance Index Core Facility, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare J","family":"Saunders","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"},{"name":"European Cystic Fibrosis Society, Lung Clearance Index Core Facility, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Department of Child Life and Health, The University of Edinburgh, Edinburgh, UK"},{"name":"Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-8477","authenticated-orcid":false,"given":"Zoe Louise","family":"Saynor","sequence":"additional","affiliation":[{"name":"University Hospitals Southampton NHS Foundation Trust, Southampton, UK"},{"name":"School of Health Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2026040308251441000_13.1.e003905.1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S2213-2600(13)70182-6","article-title":"Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial","volume":"1","author":"Davies","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026040308251441000_13.1.e003905.2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026040308251441000_13.1.e003905.3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040308251441000_13.1.e003905.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0392OC"},{"key":"2026040308251441000_13.1.e003905.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.022590"},{"key":"2026040308251441000_13.1.e003905.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.11.006"},{"key":"2026040308251441000_13.1.e003905.7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jcf.2020.10.007","article-title":"Utility of lung clearance index in CF: What we know, what we don\u2019t know and musings on how to bridge the gap","volume":"19","author":"Short","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026040308251441000_13.1.e003905.8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1513\/AnnalsATS.202006-584OC","article-title":"Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis","volume":"19","author":"O\u2019Neill","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026040308251441000_13.1.e003905.9","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00363-2019","article-title":"Multiple breath washout in bronchiectasis clinical trials: is it feasible?","volume":"6","author":"O\u2019Neill","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026040308251441000_13.1.e003905.10","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(23)00217-5","article-title":"WS06.01 Outcome measures for assessment of lung function \u2013 cross-sectional analysis of relationships between impulse oscillometry, electrical impedance tomography, multiple breath washout and spirometry","volume":"22","author":"Stanford","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026040308251441000_13.1.e003905.11","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(22)00231-4","article-title":"WS14.01 Outcome measures for airway clearance \u2013 better the devil you know? Perspectives from adults with cystic fibrosis (CF)","volume":"21","author":"Stanford","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026040308251441000_13.1.e003905.12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jcf.2025.08.005","article-title":"Feasibility of multiple-breath washout in the clinical setting and prediction of its duration in children and adults with cystic fibrosis","volume":"24","author":"Allomba","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026040308251441000_13.1.e003905.13","doi-asserted-by":"crossref","DOI":"10.3310\/nihropenres.13347.1","article-title":"Exercise as an Airway Clearance Technique in people with Cystic Fibrosis (ExACT-CF): rationale and study protocol for a randomised pilot trial","volume":"2","author":"Urquhart","year":"2022","journal-title":"NIHR Open Res"},{"key":"2026040308251441000_13.1.e003905.14","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2025-223080"},{"key":"2026040308251441000_13.1.e003905.15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02398-2021","article-title":"Normative multiple-breath washout data in school-aged children corrected for sensor error","volume":"60","author":"Kentgens","year":"2022","journal-title":"Eur Respir J"},{"key":"2026040308251441000_13.1.e003905.16","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71470","article-title":"Exploring Exercise as Airway Clearance in Cystic Fibrosis: A Qualitative Study From the ExACT-CF Feasibility Trial","volume":"61","author":"Taylor","year":"2026","journal-title":"Pediatr Pulmonol"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:25:23Z","timestamp":1775229923000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,3]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjresp-2025-003905"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003905","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}